澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - epoprostenol sodium, quantity: 531 microgram (equivalent: epoprostenol, qty 500 microgram) - powder - excipient ingredients: arginine; sodium hydroxide; sucrose - veletri is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with:,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with the scleroderma spectrum of diseases

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - epoprostenol sodium, quantity: 1.593 mg (equivalent: epoprostenol, qty 1.5 mg) - powder - excipient ingredients: arginine; sodium hydroxide; sucrose - veletri is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with:,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with the scleroderma spectrum of diseases

美国 - 英文 - NLM (National Library of Medicine)

teva parenteral medicines, inc. - epoprostenol sodium (unii: 4k04iq1of4) (epoprostenol - unii:dcr9z582x0) - epoprostenol 0.5 mg - epoprostenol sodium for injection is indicated for the treatment of pulmonary arterial hypertension (pah) (who group i) to improve exercise capacity. trials establishing effectiveness included predominantly (97%) patients with new york heart association (nyha) functional class iii-iv symptoms and etiologies of idiopathic or heritable pah (49%) or pah associated with connective tissue diseases (51%). epoprostenol is contraindicated in patients with heart failure caused by reduced left ventricular ejection fraction [see clinical studies ( 14.3)] . epoprostenol is contraindicated in patients with a hypersensitivity to the drug or any of its ingredients. risk summary limited published data from case series and case reports have not established an association with epoprostenol and major birth defects, miscarriage or adverse maternal or fetal outcomes when epoprostenol is used during pregnancy. there are risks to the mother and fetus from untreated pulmonary arterial hypertension (see clinical considerations) . in

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

ph10.5) for solution for infusion vials (sandoz ltd - epoprostenol sodium - powder and solvent for solution for infusion - 500microgram

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

ph10.5) for solution for infusion vials (sandoz ltd - epoprostenol sodium - powder and solvent for solution for infusion - 1.5mg

马耳他 - 英文 - Malta Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - epoprostenol sodium - powder and solvent for solution for infusion - epoprostenol sodium 0.531 mg - antithrombotic agents

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

drehm pharma gmbh - epoprostenol - pdr+solv for soln for inf - 500 microgram

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

drehm pharma gmbh - epoprostenol - pdr+solv for soln for inf - 1.5 milligram

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - epoprostenol sodium -

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - epoprostenol sodium -